Michelle Greenman is Vice President, Regulatory Affairs at Fate Therapeutics and is responsible for overseeing all aspects of global regulatory affairs, including regulatory strategy, submission management, regulatory CMC, and regulatory operations. Prior to joining Fate, Ms. Greenman was Vice President of Regulatory Affairs at Kezar Life Sciences, Inc., a clinical-stage biotechnology company evaluating small molecule therapeutics in various autoimmune diseases and oncology. Additionally, Ms. Greenman previously held roles at Travere Therapeutics/Retrophin, Vital Therapies, Shire Regenerative Medicine, and Advanced BioHealing and her background spans small molecules, biologics, devices, and combination products. She holds a B.A. degree in Biology from Gustavus Adolphus College and completed a graduate certificate program in Regulatory Science at the University of Southern California.